Patents Assigned to c/o Enzo Biochem, Inc.
-
Publication number: 20200069611Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).Type: ApplicationFiled: September 17, 2019Publication date: March 5, 2020Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth UniversityInventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
-
Publication number: 20190145964Abstract: Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.Type: ApplicationFiled: November 28, 2018Publication date: May 16, 2019Applicant: Enzo Life Science, Inc. c/o Enzo Biochem, Inc.Inventors: Jack Coleman, Maciej Szczepanik, Richard Jin
-
Publication number: 20190111007Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.Type: ApplicationFiled: November 26, 2018Publication date: April 18, 2019Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth UniversityInventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
-
Publication number: 20190002491Abstract: Provided are methods for labeling target molecules, such as nucleic acids, with fluorescent dye compounds having the formula One method embodiment includes contacting reactive group Z of the fluorescent dye compound with the target molecule such that reactive group Z reacts with the target molecule to form a covalent bond between the group and the target molecule. Another method embodiment includes contacting a fluorescent dye compound that further includes a first member of a binding pair, with a target molecule that includes a second member of the binding pair. Also provided are target molecules labeled with the fluorescent dye compounds.Type: ApplicationFiled: September 11, 2018Publication date: January 3, 2019Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Zaiguo Li, Praveen Pande
-
Publication number: 20180235907Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).Type: ApplicationFiled: April 16, 2018Publication date: August 23, 2018Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth UniversityInventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
-
Publication number: 20180127455Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.Type: ApplicationFiled: December 21, 2017Publication date: May 10, 2018Applicant: Enzo Life Science, Inc., c/o Enzo Biochem, Inc.Inventors: Jack Coleman, Elazar Rabbani, Jannis Stavrianopoulos, Praveen Pande
-
Publication number: 20180127456Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.Type: ApplicationFiled: December 21, 2017Publication date: May 10, 2018Applicant: Enzo Life Science, Inc., c/o Enzo Biochem, Inc.Inventors: Jack Coleman, Elazar Rabbani, Jannis Stavrianopoulos, Praveen Pande
-
Publication number: 20170315113Abstract: Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.Type: ApplicationFiled: May 31, 2017Publication date: November 2, 2017Applicant: Enzo Life Science, Inc., c/o Enzo Biochem, Inc.Inventors: Jack Coleman, Maciej Szczepanik, Richard Jin
-
Publication number: 20170219612Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: April 11, 2017Publication date: August 3, 2017Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Michael C. Mullenix, ROBERT ELLIOT ZIPKIN, JEFFREY KROLL ADAMS, WAYNE FORREST PATTON, JAMES J. DONEGAN
-
Publication number: 20170137863Abstract: Provided is a compound having the structure: (SIG)-(SI-MOD)m where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.Type: ApplicationFiled: January 26, 2017Publication date: May 18, 2017Applicant: ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC.Inventors: IRINA LEBEDEVA, WAYNE FORREST PATTON, MACIEJ SZCZEPANIK, YUEJUN XIANG, PRAVEEN PANDE
-
Publication number: 20170122954Abstract: Provided are methods, kits and systems for simultaneously profiling of global reactive species and selected reactive species, such as global and specific reactive oxygen species (ROS), reactive nitrogen species (RNS), reactive halogen species (RHS) or combinations thereof through multiplexed fluorescence detection of three or more compatible indicator probes in live cells or subcellular organelles.Type: ApplicationFiled: January 10, 2017Publication date: May 4, 2017Applicant: ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC.Inventors: IRINA LEBEDEVA, WAYNE FORREST PATTON
-
Publication number: 20160317472Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).Type: ApplicationFiled: June 14, 2016Publication date: November 3, 2016Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth UniversityInventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
-
Publication number: 20160319015Abstract: The present invention relates to methods for treating inflammatory bowel disease and other indications by inhibiting leptin activity.Type: ApplicationFiled: July 7, 2016Publication date: November 3, 2016Applicant: ENZO THERAPEUTICS. INC. C/O ENZO BIOCHEM, INC.Inventors: Yaron Ilan, Eran Elinav
-
Publication number: 20160311846Abstract: Provided are methods for labeling target molecules, such as nucleic acids, with fluorescent dye compounds having the formula One method embodiment includes contacting reactive group Z of the fluorescent dye compound with the target molecule such that reactive group Z reacts with the target molecule to form a covalent bond between the group and the target molecule. Another method embodiment includes contacting a fluorescent dye compound that further includes a first member of a binding pair, with a target molecule that includes a second member of the binding pair. Also provided are target molecules labeled with the fluorescent dye compounds.Type: ApplicationFiled: July 8, 2016Publication date: October 27, 2016Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Zaiguo Li, Praveen Pande
-
Publication number: 20160025716Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.Type: ApplicationFiled: September 3, 2015Publication date: January 28, 2016Applicant: Enzo Life Science, Inc., c/o Enzo Biochem, Inc.Inventors: Jack Coleman, Elazar Rabbani, Jannis Stavrianopoulos, Praveen Pande
-
Publication number: 20150191768Abstract: Provided is a compound comprising the structure: (SIG)-(SI-MOD)m. In this compound, SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. With this compound, when MOD is modified by an activator, SI is destabilized and self cleaved from SIG such that SIG generates an increased signal. Also provided is a method of determining whether a sample comprises an activator, using the above-described compound. Additionally provided is a method of determining whether a cell comprises a nitroreductase using the above-described compound where nitroreductase is the activator. Further provided is a method of determining whether a mammalian cell is hypoxic using the above-described compound where nitroreductase is the activator.Type: ApplicationFiled: July 31, 2014Publication date: July 9, 2015Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: MACIEJ SZCZEPANIK, IRINA V. LEBEDEVA, YUEJUN XIANG, PRAVEEN PANDE, WAYNE FORREST PATTON
-
Publication number: 20150192564Abstract: This invention provides methods, kits and systems which permit simultaneous profiling of multiple reactive oxygen species (ROS), reactive nitrogen species (RNS) and/or reactive halogen species (RHS) including reactive chlorine species (RCS) and/or reactive bromine species (RBS) through multiplexed fluorescence detection of three or more indicator probes in live cells or subcellular organelles.Type: ApplicationFiled: February 24, 2015Publication date: July 9, 2015Applicant: ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC.Inventors: IRINA LEBEDEVA, WAYNE FORREST PATTON
-
Publication number: 20150140004Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: December 16, 2014Publication date: May 21, 2015Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: MICHAEL C. MULLENIX, ROBERT ELLIOT ZIPKIN, JEFFREY KROLL ADAMS, WAYNE FORREST PATTON, JAMES J. DONEGAN
-
Publication number: 20150132287Abstract: The present invention is directed to methods for modulating the Th/Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder.Type: ApplicationFiled: January 16, 2015Publication date: May 14, 2015Applicant: ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC.Inventors: YARON ILAN, ERAN ELINAV
-
Publication number: 20150104817Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: December 16, 2014Publication date: April 16, 2015Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan